Literature DB >> 18371177

Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy.

An Claes1, Janneke Schuuring, Sandra Boots-Sprenger, Sandra Hendriks-Cornelissen, Marieke Dekkers, Albert J van der Kogel, William P Leenders, Pieter Wesseling, Judith W Jeuken.   

Abstract

Most human gliomas are characterized by diffuse infiltrative growth in the brain parenchyma. Partly because of this characteristic growth pattern, gliomas are notorious for their poor response to current therapies. Many animal models for human gliomas, however, do not display this diffuse infiltrative growth pattern. Furthermore, there is a need for glioma models that represent adequate genocopies of different subsets of human gliomas (e.g., oligodendrogliomas). Here, we assessed the intracerebral growth patterns and copy number changes [using multiplex ligation-dependent probe amplification (MLPA)/comparative genomic hybridization (CGH)] of 15 human glioma lines in nude mice. Most xenografts present with compact growing lesions intracerebrally. Only the E98 and, to a lesser degree, E106 xenograft lines (propagated through subcutaneous growth) consistently produced intracerebral tumors, displaying diffuse infiltrative growth in the brain parenchyma. In contrast, four xenograft lines (E434, E468, E473 and E478), established by direct intracerebral inoculation of human glioma cells and serially propagated intracerebrally, consistently showed extensive diffuse infiltration throughout the brain. After several passages, the neoplastic cells still carry typical chromosomal aberrations [(-1p/-19q in oligodendroglioma, +7/-10 in glioblastoma multiforme (GBM)]. Especially these latter four models and the E98 line thus represent adequate geno- and phenocopies of human gliomas and form an attractive platform to investigate different therapeutic approaches in a preclinical setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18371177     DOI: 10.1111/j.1750-3639.2008.00141.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  29 in total

1.  Adaptive adhesion systems mediate glioma cell invasion in complex environments.

Authors:  Pavlo G Gritsenko; Peter Friedl
Journal:  J Cell Sci       Date:  2018-08-13       Impact factor: 5.285

Review 2.  Review: insights gained from modelling high-grade glioma in the mouse.

Authors:  S L Rankin; G Zhu; S J Baker
Journal:  Neuropathol Appl Neurobiol       Date:  2012-06       Impact factor: 8.090

3.  In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.

Authors:  Shahryar E Mir; Philip C De Witt Hamer; Przemek M Krawczyk; Leonora Balaj; An Claes; Johanna M Niers; Angela A G Van Tilborg; Aeilko H Zwinderman; Dirk Geerts; Gertjan J L Kaspers; W Peter Vandertop; Jacqueline Cloos; Bakhos A Tannous; Pieter Wesseling; Jacob A Aten; David P Noske; Cornelis J F Van Noorden; Thomas Würdinger
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

4.  Multivoxel ¹H MR spectroscopy is superior to contrast-enhanced MRI for response assessment after anti-angiogenic treatment of orthotopic human glioma xenografts and provides handles for metabolic targeting.

Authors:  Bob Hamans; Anna Catharina Navis; Alan Wright; Pieter Wesseling; Arend Heerschap; William Leenders
Journal:  Neuro Oncol       Date:  2013-10-24       Impact factor: 12.300

5.  Patient-derived xenografts recapitulate molecular features of human uveal melanomas.

Authors:  Cécile Laurent; David Gentien; Sophie Piperno-Neumann; Fariba Némati; André Nicolas; Bruno Tesson; Laurence Desjardins; Pascale Mariani; Audrey Rapinat; Xavier Sastre-Garau; Jérôme Couturier; Philippe Hupé; Leanne de Koning; Thierry Dubois; Sergio Roman-Roman; Marc-Henri Stern; Emmanuel Barillot; J William Harbour; Simon Saule; Didier Decaudin
Journal:  Mol Oncol       Date:  2013-02-26       Impact factor: 6.603

6.  Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.

Authors:  Qingyu Zhou; James M Gallo
Journal:  Neuro Oncol       Date:  2008-10-29       Impact factor: 12.300

7.  Expression sites of colligin 2 in glioma blood vessels.

Authors:  Dana Mustafa; Marcel van der Weiden; PingPin Zheng; Alex Nigg; Theo M Luider; Johan M Kros
Journal:  Brain Pathol       Date:  2009-12-05       Impact factor: 6.508

Review 8.  Protein tyrosine phosphatases in glioma biology.

Authors:  Anna C Navis; Monique van den Eijnden; Jan T G Schepens; Rob Hooft van Huijsduijnen; Pieter Wesseling; Wiljan J A J Hendriks
Journal:  Acta Neuropathol       Date:  2009-11-21       Impact factor: 17.088

9.  Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2.

Authors:  Anna C Navis; Annika Bourgonje; Pieter Wesseling; Alan Wright; Wiljan Hendriks; Kiek Verrijp; Jeroen A W M van der Laak; Arend Heerschap; William P J Leenders
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

10.  A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1.

Authors:  Barbara Klink; Hrvoje Miletic; Daniel Stieber; Peter C Huszthy; Jaime Alberto Campos Valenzuela; Jaime Alberto Campos Valenzuela; Jörg Balss; Jian Wang; Manja Schubert; Per Øystein Sakariassen; Terje Sundstrøm; Anja Torsvik; Mads Aarhus; Rupavathana Mahesparan; Andreas von Deimling; Lars Kaderali; Simone P Niclou; Evelin Schröck; Rolf Bjerkvig; Janice M Nigro
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.